Arnav Srivastava retweeted
Match results are in! 🎉
Please join us in welcoming Malik Wahba, MD, our 2027 Urologic Oncology Fellow. Malik joins us from New York Presbyterian Hospital/Weill Cornell Medicine, and we are thrilled to have him join the Michigan Urology family! #Urology #UrologicOncology #GoBlue
Please join us in welcoming Malik Wahba, MD, our 2027 Urologic Oncology Fellow. Malik joins us from New York Presbyterian Hospital/Weill Cornell Medicine, and we are thrilled to have him join the Michigan Urology family! #Urology #UrologicOncology #GoBlue
0
6
45
2,966
Arnav Srivastava retweeted
It was a real pleasure to be involved in the recent @NCIDirector visit to @UMRogelCancer. Grateful Dr. Letai carved away time to hear what we're up to in Ann Arbor, and it was great learning about some current @theNCI priorities related to conduct of clinical trials. #GoBlue
2
4
46
2,900
Looking forward to #SUO this year in Phoenix. For any residents and/or upcoming SUO applicants, please reach out if you have any questions about our terrific urologic oncology fellowship at @UMichUrology
@SUO_YUO
@UroOnc
@SUO_YUO
@UroOnc
0
4
7
976
Arnav Srivastava retweeted
BCG-unresponsive NMIBC trials feel confusing—and inconsistent EFS reporting is a big reason why
We analyze the CIS+ cohorts of 4-FDA registration trials to provide interpretable EFS estimates
🧵👇
@Annals_Oncology
@tompowles1
@JoshMeeks
@wandering_gu
doi.org/10.1016/j.anno…
We analyze the CIS+ cohorts of 4-FDA registration trials to provide interpretable EFS estimates
🧵👇
@Annals_Oncology
@tompowles1
@JoshMeeks
@wandering_gu
doi.org/10.1016/j.anno…
1
15
36
10,953
Great work by @Daws_Hill, one of our med students at @UMichUrology
Mentorship by @hollenbeck1971 and @VahaknS
Mentorship by @hollenbeck1971 and @VahaknS
Black men with newly diagnosed prostate cancer were less likely to receive confirmatory testing, indicating poorer care, but also less likely to be overtreated, according to this cross-sectional study. ja.ma/3GZCvFK @4rnav
0
0
5
1,083
Arnav Srivastava retweeted
Among two U.S prostate cancer registries, the proportion of patients undergoing prostatectomy for indolent cancer dropped over five-fold from 2010 to 2024. ja.ma/3TGuJUa @monda_steven @4rnav @MUSICurology @wandering_gu
0
4
12
2,153
Arnav Srivastava retweeted
Welcome, Dr. Jason Qian! We're thrilled to announce our 2026 Society of Urologic Oncology (SUO) Fellow, who will be joining us from his residency at Massachusetts General Brigham. Welcome to Michigan Urology! 💙💛
1
9
54
4,417
Next cycle fellowship cycle!
Melinda Fu @MelindaFu3 (@SUO_YUO)
Raeesa Islam @IslamRaeesa (@SocietyGURS )
Talented residents, both with high profile podium presentations at #AUA2025
Melinda Fu @MelindaFu3 (@SUO_YUO)
Raeesa Islam @IslamRaeesa (@SocietyGURS )
Talented residents, both with high profile podium presentations at #AUA2025
0
2
18
1,249
Incredibly proud of my former junior residents, Rachel Passarelli @rpassarellimd (@SocietyGURS) and John Pfail @JohnPfail (@SPU_Urology), now applying for fellowships.
Both phenomenal surgeons leading their own science
@rwjurology
#AUA2025
Both phenomenal surgeons leading their own science
@rwjurology
#AUA2025
0
0
6
514
Arnav Srivastava retweeted
1/
Has there been an improvement in surgical overtreatment of prostate cancer over the past 2 decades?
Yes — and profoundly.
In 2010, 1 in 3 prostatectomies 🔪 were for indolent disease.
In 2024, it's 1 in 20.
Read our work below, presented at #AUA2025 today. 🧵
Has there been an improvement in surgical overtreatment of prostate cancer over the past 2 decades?
Yes — and profoundly.
In 2010, 1 in 3 prostatectomies 🔪 were for indolent disease.
In 2024, it's 1 in 20.
Read our work below, presented at #AUA2025 today. 🧵
Among two US prostate cancer registries, the proportion of patients undergoing prostatectomy for indolent cancer dropped over five-fold from 2010 to 2024.
ja.ma/4jSSDGZ
3
10
27
4,648
Arnav Srivastava retweeted
Wonderful night with old and new friends at the #AUA25 Dow HSR Division Dinner
0
2
13
527
Terrific work on a podium presentation by @Daws_Hill, one of our best medical students at @UMichUrology who will be applying for urology residency soon enough.
A smooth presentation at the intersection of disparities, quality, and utilization in prostate cancer.
A smooth presentation at the intersection of disparities, quality, and utilization in prostate cancer.
0
0
7
366
Many thanks to the @AmerUrological for their support and interest in the work we are doing at @UMichUrology!
As health services researchers, the policy lens of what we do often determines the impact of our work
@BenPockros @CatherineSNamMD
As health services researchers, the policy lens of what we do often determines the impact of our work
@BenPockros @CatherineSNamMD
#AUASummit25 is almost over, but we still have a couple of exciting presentations left, including one starting now with @4rnav. In his presentation, he will discuss aligning payment models and quality in prostate cancer care, including the rationale for new payment models, current payment strategies and disease-specific payment models.
1
3
28
2,365
As the @SUO_YUO interview season please reach out with any questions about our program or the process in general
Many great programs out there. But if you want to be a surgeon-scientist, there is no place like @UMichUrology
Many great programs out there. But if you want to be a surgeon-scientist, there is no place like @UMichUrology
🌟 Spotlight on our exceptional SUO Research Fellows!
Their dedication to advancing urologic oncology through groundbreaking research is driving innovation and improving patient outcomes!
0
3
13
1,875
Arnav Srivastava retweeted
Thrilled to announce that our program is expanding from 2–>3 residents/year starting with this upcoming intern class. Thank you to our fearless leaders @TomJangUroOnc and Dr. Barone for their unwavering determination to get this done 🙌
4
11
56
3,764
Some of our work in alternative payment development and evaluation at @UMichUrology in collaboration with @MUSICUrology
APM development remains very challenging ... but also potentially very promising
@VahaknS
@hollenbeck1971
@UM_IHPI
APM development remains very challenging ... but also potentially very promising
@VahaknS
@hollenbeck1971
@UM_IHPI
A payment incentive was not linked with more active surveillance adoption in men with low-risk prostate cancer vs the preincentive period. ja.ma/4a7AC3Y @4rnav @MUSICurology
1
1
22
1,436
For any residents and/or upcoming SUO applicants, please reach out if you have any questions about our terrific urologic oncology fellowship at @UMichUrology or the fellowship process in general
@SUO_YUO
@UroOnc
@SUO_YUO
@UroOnc
0
1
8
1,011
Arnav Srivastava retweeted
How do commercial prices affect #ProstateCancer care in patients insured by Medicare? New research from @4rnav et al explains more: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @Oncoalert #PCSM CC: @WalterStadler5
0
2
4
958